Current Partnerships for Canakinumab Biosimilars
Alvotech has partnered with STADA Arzneimittel for the development and commercialization of AVT02, a proposed biosimilar to Ilaris (canakinumab). STADA holds exclusive rights in Europe, while Alvotech retains rights elsewhere.[1]
Intas Pharmaceuticals collaborates with Biocon Biologics on a canakinumab biosimilar candidate, leveraging Biocon's manufacturing expertise for global markets.[2]
Which Companies Are Developing Canakinumab Biosimilars?
Several firms are advancing candidates without announced partnerships:
- Formycon and Bioeq pursue FYB202, with Phase 3 trials ongoing and no public partners.
- Richter-Helm Bioteknik and Gedeon Richter develop a biosimilar, focusing on European approval.
- Zydus Lifesciences works on a candidate, primarily for India and emerging markets.[3]
No U.S.-specific partnerships have been disclosed, as no biosimilars are approved there yet.
How Do These Compare to Novartis's Original Patent Strategy?
Novartis holds patents on canakinumab until at least 2030 in major markets, including formulation and manufacturing processes. Biosimilar developers like Alvotech challenge these via litigation, similar to strategies against Humira biosimilars. DrugPatentWatch tracks 14 Orange Book patents for Ilaris, with expirations staggered through 2034.[4]
When Might Biosimilars Launch?
European launches could occur by 2026-2027 post-EMA approval, assuming trials succeed. AVT02 completed Phase 3 in 2023, positioning it ahead. U.S. entry likely delays until 2030+ due to patent thickets.[1][3]
What Drives These Partnership Choices?
Biosimilar partnerships pair developers (e.g., Alvotech's innovation) with commercial experts (e.g., STADA's EU network) to share costs and risks. Intas-Biocon emphasizes scalable production for price-sensitive markets.[2]
Sources
[1]: Alvotech-STADA press release
[2]: Biocon-Intas partnership details
[3]: GaBI Online biosimilar pipeline tracker
[4]: DrugPatentWatch.com - Ilaris patents